Universidad Complutense de Madrid-ko ikertzaileekin lankidetzan egindako argitalpenak (10)

2024

  1. Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: Discover study

    Multiple Sclerosis and Related Disorders, Vol. 90

  2. Defining a standard set of health outcomes for patients with relapsing-remitting multiple sclerosis

    Multiple Sclerosis and Related Disorders, Vol. 84

2022

  1. Cannabinoid CB1 receptor expression in oligodendrocyte progenitors of the hippocampus revealed by the NG2-EYFP-knockin mouse

    Frontiers in Neuroanatomy, Vol. 16

  2. Cannabinoid CB1 receptor gene inactivation in oligodendrocyte precursors disrupts oligodendrogenesis and myelination in mice

    Cell Death and Disease, Vol. 13, Núm. 7

  3. Consensus statement on the use of alemtuzumab in daily clinical practice in Spain

    Neurologia, Vol. 37, Núm. 8, pp. 615-630

  4. Disease modifying therapy switching in relapsing multiple sclerosis: A Delphi consensus of the demyelinating expert group of the Spanish society of neurology

    Multiple Sclerosis and Related Disorders, Vol. 63

2021

  1. Δ9-Tetrahydrocannabinol promotes functional remyelination in the mouse brain

    British Journal of Pharmacology, Vol. 178, Núm. 20, pp. 4176-4192

  2. Δ9-Tetrahydrocannabinol promotes oligodendrocyte development and CNS myelination in vivo

    GLIA, Vol. 69, Núm. 3, pp. 532-545

2018

  1. Deregulation of the endocannabinoid system and therapeutic potential of ABHD6 blockade in the cuprizone model of demyelination

    Biochemical Pharmacology, Vol. 157, pp. 189-201

2016

  1. BDNF and NGF Signalling in Early Phases of Psychosis: Relationship with Inflammation and Response to Antipsychotics after 1 Year

    Schizophrenia Bulletin, Vol. 42, Núm. 1, pp. 142-151